MicroTransponder
PrivateLast Round
Series F
Mar 12, 2025
Est. Valuation
$225M
Total Funding Raised
$174.64M
Company Overview
MicroTransponder operates in Healthcare & Life Sciences and is based in Austin, Texas. Its latest recorded funding round was a Series F round in March 2025.
MicroTransponder is a medical technology company that develops nerve stimulation-based therapies aimed at treating stroke rehabilitation, tinnitus, and various neurological conditions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MicroTransponder Comparables
Compare MicroTransponder with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kandu Health | 72% | |
| Myomo Inc | 71% | |
| Solana Company | 68% |
For institutional investors. Book with your work email.
MicroTransponder Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F | Mar 12, 2025 | ||||
| Series E | Sep 21, 2022 | ||||
| Debt | Sep 8, 2020 | ||||
| Series C | Nov 17, 2017 | ||||
| VC Round | Dec 10, 2015 | ||||
VC Round | Aug 29, 2013 |
For institutional investors. Book with your work email.
MicroTransponder Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series F |
| The Vertical Group | Series E, Series F |
| Action Potential Venture Capital | Series E, Series F |
| U.S. Venture Partners | Series E, Series F |
| Osage University Partners | Series E, Series F |
| GPG Ventures | Series E, Series F |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 25, 2025
Medicare payment change announced for Vivistim procedure, improving reimbursement and market access.
- Nov 17, 2025
Cynthia Lucchese joins as an independent director.
For institutional investors. Book with your work email.
MicroTransponder Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MicroTransponder's valuation, stock price, and market status.
Is MicroTransponder a public or private company?
MicroTransponder is a private company.
What is the current stock price of MicroTransponder?
MicroTransponder is a private company, so its shares have no public market price. Caplight tracks MicroTransponder's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MicroTransponder worth (valuation)?
MicroTransponder's valuation is estimated at $225.0M based on funding round data.
Can I buy MicroTransponder stock?
MicroTransponder shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MicroTransponder's last funding round?
MicroTransponder's most recent funding round was Series F on March 12, 2025.
Who are the main investors in MicroTransponder?
Key investors in MicroTransponder include U.S. Venture Partners, Green Park & Golf Ventures.
Will MicroTransponder IPO soon?
No public IPO plans have been announced for MicroTransponder.
How can I track MicroTransponder secondary market activity?
Caplight tracks bids, offers, and trades in MicroTransponder's shares on secondary markets.